Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.08 – $1.75
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $381.8M | $422.1M | $452.4M | $503.8M | $560.1M | $650.5M | $713.8M | $806.5M |
| Cost of revenue | $301.5M | $377.9M | $427.7M | $501.9M | $579.9M | $651.9M | $454.0M | $824.4M |
| Gross profit | $80.3M | $44.2M | $24.7M | $1.8M | −$19.8M | −$1.3M | $713.8M | −$17.9M |
| Gross margin | 21.0% | 10.5% | 5.5% | 0.4% | -3.5% | -0.2% | 100.0% | -2.2% |
| R&D | $0 | $3.6M | $5.1M | $5.1M | $11.7M | $16.1M | $0 | $0 |
| Operating income | $54.9M | $44.2M | $24.7M | $1.8M | −$19.8M | −$69.6M | −$118.3M | −$17.9M |
| EBITDA | $75.5M | $218.8M | $461.9M | $788.2M | $458.0M | −$50.7M | −$27.2M | $25.0M |
| Net income | $326.0M | $264.7M | $423.1M | $692.9M | $257.8M | $4.8M | −$436.8M | −$173.1M |
| Net margin | 85.4% | 62.7% | 93.5% | 137.5% | 46.0% | 0.7% | -61.2% | -21.5% |
| EPS (diluted) | 0.65 | 0.50 | 0.80 | 1.31 | 0.50 | 0.01 | -0.61 | -0.17 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $524M | $0.03 | $0.03–$0.04 | 1 |
| 2028 | $561M | $0.06 | $0.05–$0.07 | 1 |
| 2029 | $593M | $0.08 | $0.07–$0.09 | 1 |
| 2030 | $599M | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
RYMAN HEALTHCARE ORD
No one on the platform currently holds RHCGF.
No tracked institution reports a position in RHCGF as of their last filing.
No one on the platform has traded RHCGF yet.
| +0.00% |
| $743M |
| — |
| MAHLYMediPal Holdings Corporation | $16.28 | +0.00% | $3.3B | — |
| MCVEFMedicover AB (publ) | $27.25 | +0.00% | $4.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 2.2× earnings vs its 7.1× historical median P/E.
Fair value ≈ $3.48 · price $1.08 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.